-
![IMIDAZO[1,2-A]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS](/abs-image/US/2012/01/12/US20120010209A1/abs.jpg.150x150.jpg)
41.发明申请IMIDAZO[1,2-A]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS 有权咪唑并[1,2-A]吡啶和咪唑并[1,2-b]吡啶类作为标记抑制剂公开(公告)号：US20120010209A1
公开(公告)日：2012-01-12
申请号：US13144123
申请日：2010-01-12
Applicant: Michael D. Altman , Mark T. Bilodeau , Jongwon Lim , Alan Nortrup , Matthew G. Stanton , Brandon M. Taoka
Inventor： Michael D. Altman , Mark T. Bilodeau , Jongwon Lim , Alan Nortrup , Matthew G. Stanton , Brandon M. Taoka
IPC: A61K31/5025 , A61P25/28 , A61K31/437 , C07D487/04 , C07D471/04
CPC classification number: A61K31/5025 , C07D471/04 , C07D487/04
Abstract: The invention encompasses imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
Abstract translation: 本发明包括选择性抑制微管亲和调节激酶（MARK）的咪唑并[1,2-a]吡啶和咪唑并[1,2-b]哒嗪衍生物，因此可用于治疗或预防阿尔茨海默氏病。 还包括药物组合物和使用方法。
-
公开(公告)号：US20110178092A1
公开(公告)日：2011-07-21
申请号：US11960120
申请日：2007-12-19
Applicant: Akbar Ali , Michael D. Altman , Saima G. Anjum , Hong Cao , Sripriya Chellappan , Miguel X. Fernandes , Michael K. Gilson , Visvaldas Kairys , Nancy King , Ellen Nalivaika , Moses Prabu , Tariq M. Rana , Kiran Kumar Sai , Celia A. Schiffer , Bruce Tidor
Inventor： Akbar Ali , Michael D. Altman , Saima G. Anjum , Hong Cao , Sripriya Chellappan , Miguel X. Fernandes , Michael K. Gilson , Visvaldas Kairys , Nancy King , Ellen Nalivaika , Moses Prabu , Tariq M. Rana , Kiran Kumar Sai , Celia A. Schiffer , Bruce Tidor
IPC: A61K31/501 , C07D403/12 , A61K31/4178 , C07D401/14 , A61K31/4439 , C07D413/12 , A61K31/422 , C07C311/29 , A61K31/18 , C07D277/36 , A61K31/426 , C07D277/64 , A61K31/428 , C07C233/81 , A61K31/166 , C07D215/48 , A61K31/47 , A61P31/18
CPC classification number: C07C311/05 , C07C233/36 , C07C235/20 , C07C235/50 , C07C235/60 , C07C235/74 , C07C237/22 , C07C311/29 , C07C2601/02 , C07C2601/10 , C07C2601/14 , C07D215/48 , C07D263/24 , C07D277/36 , C07D277/64 , C07D307/20 , C07D307/79 , C07D401/14 , C07D403/12 , C07D413/12 , C07D417/12 , C07D493/04
Abstract: Described are novel protease inhibitors and methods for using said protease inhibitors in the treatment of human immunodeficiency virus (HIV) infection.
Abstract translation: 描述了新型蛋白酶抑制剂和使用所述蛋白酶抑制剂治疗人类免疫缺陷病毒（HIV）感染的方法。
-
公开(公告)号：US11311528B2
公开(公告)日：2022-04-26
申请号：US16980594
申请日：2019-03-15
Applicant: Merck Sharp & Dohme Corp. , Michael D. Altman , Matthew L. Childers , James P. Jewell , Charles A. Lesburg , Tony Siu
Inventor： Michael D. Altman , Matthew L. Childers , James P. Jewell , Charles A. Lesburg , Tony Siu
IPC: C07D405/10 , C07D405/14 , C07D409/04 , C07D411/04 , C07D413/04 , C07D413/14 , C07D417/14 , A61K31/4725 , A61K31/497 , A61K31/5377 , A61K31/538
Abstract: The instant invention provides compounds of formula I which are STING inhibitors, and as such are useful for the treatment of STING-mediated diseases such as inflammation, asthma, COPD and cancer.
-
Patent Agency Ranking
公开(公告)号：US20180051030A1
公开(公告)日：2018-02-22
申请号：US15557203
申请日：2016-03-07
Applicant: Jongwon LIM , Michael D. ALTMAN , Jason BRUBAKER , Craig R. GIBEAU , MERCK SHARP & DOHME CORP.
Inventor： JONGWON LIM , MICHAEL D. ALTMAN , JASON D. BRUBAKER , CRAIG R. GIBEAU
IPC: C07D487/04 , C07D403/14 , A61K31/53 , A61K45/06
CPC classification number: C07D487/04 , A61K31/519 , A61K31/53 , A61K45/06 , A61P29/00 , C07D403/14 , A61K2300/00
Abstract: The present invention relates to pyrrolotriazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
-
公开(公告)号：US20180051027A1
公开(公告)日：2018-02-22
申请号：US15557195
申请日：2016-03-07
Applicant: JONGWON LIM , MICHAEL D. ALTMAN , MATTHEW L. CHILDERS , CRAIG R. GIBEAU , GINNY DAI HO , HONCHUNG TSUI , MERCK SHARP & DOHME CORP.
Inventor： JONGWON LIM , MICHAEL D. ALTMAN , MATTHEW L. CHILDERS , CRAIG R. GIBEAU , GINNY DAI HO , HONCHUNG TSUI
IPC: C07D487/04 , A61K45/06 , A61K31/519 , A61K31/5377 , A61K31/635 , C07D495/04 , A61K31/4985 , A61K31/53
CPC classification number: C07D487/04 , A61K31/4985 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K31/635 , A61K45/06 , C07D495/04
Abstract: The present invention relates to carboxamide inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
-
46.发明授权2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors 有权含2-吡啶甲酰胺的脾脏酪氨酸激酶（SYK）抑制剂公开(公告)号：US09216173B2
公开(公告)日：2015-12-22
申请号：US14349551
申请日：2012-10-01
Applicant: Michael D. Altman , Corey E. Bienstock , John W. Butcher , Kaleen Konrad Childers , Maria Emilia Di Francesco , Anthony Donofrio , John Michael Ellis , Christian Fischer , Andrew M. Haidle , James P. Jewell , Sandra Lee Knowles , Alan B. Northrup , Ryan D. Otte , Scott L. Peterson , Graham Frank Smith
Inventor： Michael D. Altman , Corey E. Bienstock , John W. Butcher , Kaleen Konrad Childers , Maria Emilia Di Francesco , Anthony Donofrio , John Michael Ellis , Christian Fischer , Andrew M. Haidle , James P. Jewell , Sandra Lee Knowles , Alan B. Northrup , Ryan D. Otte , Scott L. Peterson , Graham Frank Smith
IPC: C07D213/73 , A61K31/4439 , C07D401/14 , C07D405/14 , C07D413/14 , C07D213/81 , C07D401/12 , C07D409/14 , C07D417/14 , C07D487/04 , C07D495/04 , A61K31/444 , A61K31/496 , A61K31/5025 , A61K31/506 , A61K31/519 , A61K31/5377
CPC classification number: A61K31/4439 , A61K31/444 , A61K31/496 , A61K31/5025 , A61K31/506 , A61K31/519 , A61K31/5377 , C07D213/81 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D495/04
Abstract: The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
Abstract translation: 本发明提供了具有式（I）的某些含2-吡啶甲酰胺的化合物或其药学上可接受的盐，其中A和B如本文所定义。 本发明还提供包含这些化合物的药物组合物，以及使用该化合物治疗由脾脏酪氨酸激酶（Syk）激酶介导的疾病或病症的方法。
-
公开(公告)号：US20140100250A1
公开(公告)日：2014-04-10
申请号：US14116205
申请日：2012-05-04
Applicant: Michael D. Altman , Maria Emilia Di Francesco , Andrew M. Haidle , Ryan D. Otte , John Michael Ellis , Kaleen Konrad Childers , Alan B. Northrup , Liping Wang
Inventor： Michael D. Altman , Maria Emilia Di Francesco , Andrew M. Haidle , Ryan D. Otte , John Michael Ellis , Kaleen Konrad Childers , Alan B. Northrup , Liping Wang
IPC: C07D417/14
CPC classification number: C07D417/14
Abstract: The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
Abstract translation: 本发明提供了式I的新型嘧啶胺，其是脾脏酪氨酸激酶的有效抑制剂，并且可用于治疗和预防由所述酶介导的疾病，例如哮喘，COPD，类风湿性关节炎和癌症。
-
公开(公告)号：US08551984B2
公开(公告)日：2013-10-08
申请号：US12968608
申请日：2010-12-15
Applicant: Michael D. Altman , Brian M. Andresen , Kenneth L. Arrington , Jason Burch , Kaleen Konrad Childers , Bernard Cote , Maria Emilia Di Francesco , Anthony Donofrio , Kristina Dupont-Gaudet , John Michael Ellis , Christian Fischer , Daniel Guay , David Joseph Guerin , Andrew M. Haidle , Solomon Kattar , Sandra Lee Knowles , Chaomin Li , Jongwon Lim , Michelle R. Machacek , Alan B. Northrup , Brendan M. O'Boyle , Ryan D. Otte , Michael H. Reutershan , Eric Romeo , Adam J. Schell , Tony Siu , Kerrie B. Spencer , Brandon M. Taoka , B. Wesley Trotter , Hua Zhou
Inventor： Michael D. Altman , Brian M. Andresen , Kenneth L. Arrington , Jason Burch , Kaleen Konrad Childers , Bernard Cote , Maria Emilia Di Francesco , Anthony Donofrio , Kristina Dupont-Gaudet , John Michael Ellis , Christian Fischer , Daniel Guay , David Joseph Guerin , Andrew M. Haidle , Solomon Kattar , Sandra Lee Knowles , Chaomin Li , Jongwon Lim , Michelle R. Machacek , Alan B. Northrup , Brendan M. O'Boyle , Ryan D. Otte , Michael H. Reutershan , Eric Romeo , Adam J. Schell , Tony Siu , Kerrie B. Spencer , Brandon M. Taoka , B. Wesley Trotter , Hua Zhou
IPC: C07D417/12 , A61K31/497
CPC classification number: C07D417/12 , C07D417/14 , C07D451/06 , C07D471/04 , C07D471/08 , C07D487/04 , C07D491/08 , C07D495/04 , C07F9/65583
Abstract: The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.
Abstract translation: 本发明提供了新颖的式（I）嘧啶胺，其是脾脏酪氨酸激酶的有效抑制剂，并且可用于治疗和预防由所述酶介导的疾病，例如哮喘，COPD和类风湿性关节炎。
-
-
-
-
-
-
-
Search Results
48
records
(took 0.06 seconds)
